---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-008210"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:46:33.224448+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nektar enters quiet period ahead of Phase 2b REZOLVE-AD maintenance data; data expected in February 2026

## Summary
- Quiet period begins January 27, 2026 and continues until public announcement of the maintenance data.
- Maintenance Data are from the 36-week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin.
- Next investor communication planned for February 2026 at the time of data presentation.
- This quiet period is consistent with prior quiet periods for REZOLVE studies.

## SEC filing metadata
- accession: 0001213900-26-008210
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390026008210/0001213900-26-008210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390026008210/ea0274309-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-008210
- JSON: https://secwatch.observer/filing/0001213900-26-008210.json
- Plain text: https://secwatch.observer/filing/0001213900-26-008210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.